Otonomy (NASDAQ:OTIC) Share Price Crosses Above 50-Day Moving Average of $0.11
Otonomy (NASDAQ:OTIC) Share Price Crosses Above 50-Day Moving Average of $0.11
Otonomy, Inc. (NASDAQ:OTIC – Get Rating) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $0.11 and traded as high as $0.13. Otonomy shares last traded at $0.11, with a volume of 1,365,375 shares traded.
Otonomy 公司（NASDAQ：ODDAQ-獲取評級）在周二交易期間越過其 50 天移動平均線以上。該股票的 50 天移動平均線為 0.11 美元，交易高達 0.13 美元。Otonomy 股票最後交易價為 0.11 美元，成交量為 1,365,375 股。
Analyst Ratings Changes
分析師等級變更
OTIC has been the topic of several recent analyst reports. StockNews.com initiated coverage on Otonomy in a research note on Wednesday. They issued a "hold" rating on the stock. Piper Sandler downgraded Otonomy from an "overweight" rating to a "neutral" rating and dropped their price objective for the stock from $3.00 to $0.50 in a report on Thursday, October 13th.
奧迪一直是最近幾個分析師報告的話題。Stocknews.com 在周三的一份研究報告中開始了對 Otonomy 的報導。他們對股票發出了「持有」評級。派珀·桑德勒（Piper Sandler）在 10 月 13 日（星期四）的一份報告中，將 Otonomy 從「超重」評級降至「中性」評級，並將其股票的價格目標從 3.00 美元降至 0.50 美元。
Otonomy Stock Performance
Otonomy 股票表現
The company's fifty day simple moving average is $0.11 and its two-hundred day simple moving average is $0.39. The company has a market capitalization of $6.87 million, a price-to-earnings ratio of -0.14 and a beta of 1.47.
該公司的五十天簡單移動平均線為 0.11 美元，其 200 天簡單移動平均線為 0.39 美元。該公司的市值為 687 萬美元，價格與收益比為 -0.14，測試版為 1.47。
Institutional Investors Weigh In On Otonomy
機構投資者對 Otonomy 的權衡
A number of institutional investors have recently made changes to their positions in OTIC. Silverarc Capital Management LLC lifted its stake in Otonomy by 0.6% during the first quarter. Silverarc Capital Management LLC now owns 1,207,385 shares of the biopharmaceutical company's stock worth $2,898,000 after purchasing an additional 7,571 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Otonomy by 17.7% during the first quarter. Dimensional Fund Advisors LP now owns 841,694 shares of the biopharmaceutical company's stock worth $2,020,000 after purchasing an additional 126,747 shares during the period. State Street Corp lifted its position in shares of Otonomy by 5.1% in the 1st quarter. State Street Corp now owns 182,239 shares of the biopharmaceutical company's stock worth $437,000 after buying an additional 8,839 shares during the last quarter. Two Sigma Investments LP grew its position in shares of Otonomy by 129.2% during the 3rd quarter. Two Sigma Investments LP now owns 142,183 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 80,153 shares during the last quarter. Finally, Requisite Capital Management LLC acquired a new stake in Otonomy during the third quarter worth about $44,000. 41.23% of the stock is currently owned by institutional investors.
不少機構投資者最近更改了他們在奧迪的倉位。銀弧資本管理有限責任公司在第一季度將其在 Otonomy 的股份提升了 0.6%。銀凱資本管理有限責任公司在上個季度額外購買 7,571 股股票後，現在擁有該生物製藥公司股票的 1,207,385 股價值 2,898,000 美元。維基金顧問有限公司在第一季度將其 Otonomy 股份的持有量提高了 17.7%。維基金顧問有限公司在此期間額外購買 126,747 股股票後，現在擁有該生物製藥公司的 841,694 股股價值 2,020,000 美元。州街公司在第一季度將其在 Otonomy 股份中的位置提高了 5.1％。州街公司現在擁有該生物製藥公司的 182,239 股股票，價值 437,000 美元，在上一季度額外購買 8,839 股股票。兩西格瑪投資 LP 在第三季度增長了其在 Otonomy 股份的地位 129.2％。兩個西格瑪投資 LP 現在擁有 142,183 股的生物製藥公司的股票，價值為 42,000 美元，在上個季度購買了 80,153 股後。最後，必要資本管理有限責任公司在第三季度收購了 Otonomy 的新股份，價值約為 44,000 美元。41.23％ 的股票目前由機構投資者擁有。
About Otonomy
關於「音樂」
(Get Rating)
(取得評分)
Otonomy, Inc operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss.
Otonomy, Inc 是一家生物製藥公司。從事神經病學治療藥物的開發。該公司的產品線包括奧替維克斯（地塞米松）梅尼爾氏病，奧替普利（環丙沙星懸浮液）急性中耳炎，帶管（AOMT），OTO-313（加基克列定）耳鳴，OTO-413（BDNF）隱性聽力損失，OTO-510（耳保護劑）防止耳朵重度損失（CIPHL），致聽力損失（CIHL）嚴重聽力損失（CIHL）。OTO-6XX
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Otonomy (OTIC)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
- 免費獲取有關 OTONNOMY 的研究報告
- 普利安特治療學缺口 34％ 更高：更多的上升空間來？
- 2023 年初裁員將如何影響這 5 種生物技術股票？
- 在 70％ 的峰值之後，鮑達斯生物投資者的痛苦是否已經過去？
- 火箭實驗室的第一次美國發射會將股票送入平流層嗎？
- 3 零售股票在 2023 年響起登記冊
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Otonomy 日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收 Otonomy 和相關公司的最新新聞和分析師評級的簡要每日摘要。